SPY поднимается на премаркете

Ближайший уровень поддержки по SPY – 192.25 уровень сопротивления – 193.00



WAG смотрим на рост

PRGO выше 143 покупка

OAS ниже 47 продажа

Gapping up/down: SSYS +12%, MIDD +7%, and SUNE +5% after earnings, select solar names trading higher, LIME +200% after contract win; ATML -5% and COST -1% after earnings/SSS, select metals/miners trading lower
Gapping up 
In reaction to strong earnings/guidance/SSS: SAAS +18.5%, LGP +18.4%, SSYS +12.4%, JACK +11.2%, HZNP +11%, MCP +10.8%, GDP +9.4%, TRMR +8.7%, MBI +7%, MIDD +6.7%, FOXA +5.2%, HAR +5.1%, TPH +4.8%, SUNE +4.8%, DXCM +4.7%, HIMX +4.6%, PKT +4.5%, LDRH +4.5%, EVHC +4.3%, ATHM +4.3%, CRIS +4.2%, QIWI +4.1%, DEG +3.8%, WTI +3.7%, BREW +3.5%, TROX +3.5%, EVRY +3.5%, TDC +3.4%, WWAV +3.3%, KERX +3.2%, DEPO +3.1%, MUSA +2.9%, CTL +2.9%, VNDA +2.9%, WEN +2.8%, JBT +2.6%, OFIX +2.5%, AFSI +2.5%, EXAR +2.4%, RIG +2.3%, RDN +2.3%, PACD +2.2%, DYN +2.2%, ZFGN +2.2%, AGU +2.1%, CSII +2%, ICE +2%, BKD +1.8%, TWO +1.8%, NLY +1.7%, TCAP +1.7%, AAON +1.6%, CDXS +1.5%, WR +1.5%, DNB +1.3%, TEG +1.3%, PMT +1.3%, RIO +1.3%, MRIN +1.2%, RGLD +1.2%, DUK +1.2%, ITMN +1.1%, ETP +1.1%, SN +1.1%, SYMC +1.1%, MNK +1.1%.


M&A news: CST +6.6% (CST Brands (CST) to acquire the general partner of LGP for $17 mln in cash and ~ 2.044 mln shares of CST common stock; CST authorizes repurchase of up to $200 mln of common stock ), NEM +0.8% (exec says company still open to merger with Barrick Gold (ABX), according to reports).

Select solar names showing strength: HSOL +2.9%, JASO +2.4%, TAN +2.4%, TSL +1.8%, CSIQ +1.7%, JKS +1.4%, YGE +1.2%, FSLR +0.7%.

Other news: LIME +203.8% (announced utility program contract win valued at $180 mln), OGXI +23.3% (announces appointment of John Bencich as VP and CFO), LGP +18.4% (CST Brands (CST) to acquire the general partner of LGP for $17 mln in cash and ~ 2.044 mln shares of CST common stock; CST authorizes repurchase of up to $200 mln of common stock ), MCP +10.8% (announces commitment for a $400 mln financing arrangement ), MDCO +10.6% (received FDA approval of Orbactiv (oritavancin) for the treatment of skin infections), CTRP +10% (co and Priceline Group (PCLN) expand partnership; Priceline to make $500 mln investment in Ctrip), GTXI +7.8% (filed for a ~22.156 mln share common stock shelf offering which includes ~10.18 mln shares of its common stock issuable upon the exercise of outstanding warrants, which are held by the selling stockholders), VJET +6.2% (following SSYS results), CTIC +6.1% (receives FDA Fast Track Designation for Pacritinib, a novel JAK2 Inhibitor for the treatment of myelofibrosis), XONE +5.9% (following SSYS results), PERY +4.9% (following late move higher on volume — attributed to M&A speculation), DDD +3.4% (following SSYS results), WBAI +2.1% (enters into strategic partnership with China Mobile Limited (CHL)), DB +2% (peer Commerzbank trading higher after results), VMW +1.7% (announced authorization of stock repurchase program of up to $1 bln of its Class A common stock), BKS +1.5% (Google and Barnes & Noble (BKS) want to compete with Amazon (AMZN) on speedy book delivery, according to reports), MNK +1.1% (announced settlement of OFIRMEV (acetaminophen) injection patent litigation with Fresenius Kabi USA), BAC +0.9% (reports suggesting $16.5 bln DoJ settlement).

Analyst comments: AOL +3.3% (upgraded to Buy from Hold at Cantor Fitzgerald), CCL +2.1% (upgraded to Buy from Neutral at BofA/Merrill), ANR +1.6% (upgraded to Neutral from Sell at UBS), ARMH +1.3% (upgraded to Buy from Hold at The Benchmark Company), WAG +1% (upgraded to Hold from Sell at Cantor Fitzgerald)

Gapping down
In reaction to disappointing earnings/guidance/SSS: THOR -26.4%, ELON -17%, BWC -12.6%, GEOS -9.5%, RNDY -9.5%, ANAD -9.1%, IO -8.4%, CSOD -8.2%, COUP -7.6%, TXTR -6.6%, OSUR -6%, TNGO -5.4%, ATML -5.2%, ATRS -5.2%, FTK -5.1%, ZEUS -4.9%, PHMD -4.7%, ERII -4.6%, CLDX -4.5%, ZU -4.5%, SD -4.5%, NVAX -4.1%, GPOR -3.9%, IXYS -3.9%, DVAX -3.9%, DRTX -3.7%, WIN -3.5%, CPA -3.3%, EVC -3.2%, NIHD -3.2%, BDBD -3%, CECE -3%, LAMR -3%, RDUS -2.8%, SABR -2.8%, IDCC -2.7%, FRED -2.6%, ACAS -2.4%, GMCR -2.2%, TSE -2.2%, SRPT -2%, MWE -1.9%, DSCI -1.9%, AUXL -1.8%, HIL -1.6%, MYL -1.6%, HRC -1.6%, YY -1.5%, CXW -1.5%, PRSC -1.5%, TOPS -1.5%, AGYS -1.4%, CPE -1.3%, LPI -1.3%, PHX -1.3%, CGI -1.1%, NVTL -1.1%, CTB -1%, MPEL -1%, COST -1%.

Select metals/mining stocks trading lower: TC -2.2%, AU -1.5%, AU -1.5%, HL -1.2%, HL -1.2%, IAG -1.1%, HMY -1%, BHP -0.5%, MT -0.4%.

Other news: NYMX -8% (Paul Averback sold in a private transaction for financial planning purposes 470,600 common shares of NYMX for a total consideration of $2.4 mln), UMPQ -3.5% (announces secondary offering of 15 mln shares held by Thomas H. Lee Partners and Warburg Pincus), SHPG -1.8% (still checking), PT -1.5% (still checking), YY -1.5% (Shanghai -1.3% overnight), EBS -1.3% (submits Biologics license application to FDA for Anthrax Immune Globulin Intravenous), ASTM -0.9% (filed for a $20 mln common stock offering), RSPP -0.8% (announces pricing of 10 mln shares of common stock offering at $25.65/share).

Analyst comments: NUS -0.6% (downgraded to Neutral from Overweight at JP Morgan), AET -0.6% (downgraded to Neutral from Buy at Goldman), UNH -0.6% (removed from Conviction Buy list at Goldman), PERI -0.5% (downgraded to Hold from Buy at Needham), VOD -0.4% (downgraded to Mkt Perform from Outperform at Raymond James).